Universität zu Köln

Verstovsek, Srdan, Chen, Chih-Cheng, Egyed, Miklos, Ellis, Martin, Fox, Laura, Goh, Yeow T., Gupta, Vikas ORCID: 0000-0002-1419-8607, Harrison, Claire, Kiladjian, Jean-Jacques ORCID: 0000-0002-8121-438X, Lazaroiu, Mihaela C., Mead, Adam, McLornan, Donal, McMullin, Mary F., Oh, Stephen T., Perkins, Andrew, Platzbecker, Uwe, Scheid, Christof, Vannucchi, Alessandro, Yoon, Sung-Soo, Kowalski, Mark M. and Mesa, Ruben A. (2021). MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol., 17 (12). S. 1449 - 1459. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Full text not available from this repository.

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB. Lay abstract:The most important features of myelofibrosis (MF) are low blood cell counts and symptoms including tiredness, night sweats and itching, along with increased size of the spleen, which may cause a feeling of fullness and pain. Low red blood cell counts (anemia) may mean regular blood transfusions are needed and this is one of the signs MF is getting worse. Drugs called JAK inhibitors (JAKi) are available to treat MF, but can have a side effect of making blood cell counts lower. Momelotinib (MMB) is a different type of JAKi to the ones currently available, and is an experimental drug for MF. MMB is designed to treat symptoms and spleen like other JAKi, but also to improve blood cell counts. MMB has already been given to more than 820 patients with MF in other clinical studies. Some of the patients in these studies had been treated with different JAKi before, and others got MMB as their first JAKi treatment. The MOMENTUM Phase III study is designed to collect more information on the safety and effectiveness of MMB in MF.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Verstovsek, Srdan UNSPECIFIED UNSPECIFIED UNSPECIFIED Chen, Chih-Cheng UNSPECIFIED UNSPECIFIED UNSPECIFIED Egyed, Miklos UNSPECIFIED UNSPECIFIED UNSPECIFIED Ellis, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Fox, Laura UNSPECIFIED UNSPECIFIED UNSPECIFIED Goh, Yeow T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gupta, Vikas UNSPECIFIED orcid.org/0000-0002-1419-8607 UNSPECIFIED Harrison, Claire UNSPECIFIED UNSPECIFIED UNSPECIFIED Kiladjian, Jean-Jacques UNSPECIFIED orcid.org/0000-0002-8121-438X UNSPECIFIED Lazaroiu, Mihaela C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mead, Adam UNSPECIFIED UNSPECIFIED UNSPECIFIED McLornan, Donal UNSPECIFIED UNSPECIFIED UNSPECIFIED McMullin, Mary F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Oh, Stephen T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Perkins, Andrew UNSPECIFIED UNSPECIFIED UNSPECIFIED Platzbecker, Uwe UNSPECIFIED UNSPECIFIED UNSPECIFIED Scheid, Christof UNSPECIFIED UNSPECIFIED UNSPECIFIED Vannucchi, Alessandro UNSPECIFIED UNSPECIFIED UNSPECIFIED Yoon, Sung-Soo UNSPECIFIED UNSPECIFIED UNSPECIFIED Kowalski, Mark M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mesa, Ruben A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-606093
DOI:	10.2217/fon-2020-1048
Journal or Publication Title:	Future Oncol.
Volume:	17
Number:	12
Page Range:	S. 1449 - 1459
Date:	2021
Publisher:	FUTURE MEDICINE LTD
Place of Publication:	LONDON
ISSN:	1744-8301
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTERNATIONAL WORKING GROUP; TRANSFUSION-DEPENDENCY; HEPCIDIN; ERYTHROPOIESIS; PROGNOSIS; SURVIVAL; MODEL Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/60609